Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06857487
PHASE1/PHASE2

Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke

Sponsor: Dongzhimen Hospital, Beijing

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.

Official title: Efficacy and Safety of Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Patients With Acute Ischemic Stroke : A Randomized Double-blind Placebo-controlled Pilot Trial

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

72

Start Date

2025-06-13

Completion Date

2026-10-29

Last Updated

2025-12-01

Healthy Volunteers

No

Interventions

DRUG

Qingre Huatan Formula

Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.

DRUG

Qingre Huatan Formula placebo

Qingre Huatan Formula placebo, granules, 1 bag each time, twice a day, orally, continue for 10 days.

OTHER

Guidelines-based standard care

Guidelines-based standard care for acute ischemic stroke

Locations (1)

Dongzhimen Hospital

Beijing, Beijing Municipality, China